

SOFY OF WAPERS ORIGINALLY FILED

GP1647 ,

Docket No.: PF-0510-1 CON

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on _ August 27, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of: Lal et al.

SEP 1 0 2002

Title:

HUMAN NEUROSECRETORY PROTEINS

TECH CENTER 1600/2900

Serial No.:

10/077,040

Filing Date:

February 14, 2002

Examiner:

To Be Assigned

Group Art Unit:

1647

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/062,601, filed April 17, 1998, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Docket No.: PF-0510-1 CON

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 27 August 2002

Cathleen M. Rocco
Reg. No. 46,172

Direct Dial Telephone: (650) 845-4587

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 845-4166

								
U.S. Department of Commerce, Patent and Trademark Office					Atty Docket No.		Serial No.	
•					PF-0510-1 CON		10/077,040	
LIST OF REFERENCES CITED BY APPLICANTS					Applicant(s)			
(Use several sheets if necessary)					Lal et al.			
					Filing Date		Group	
SEP 0 9 2002 2					February 14, 2002		1647	
ELE	, Pt S	-	U.S.	Patent Documents				-
*Examiner		Document					Filing I	
Initial	-	Number	Date	Name	Class	Subclass	If Appro	
	1	5,672,479	9/30/97	Johnson et al.			RECE	IVEC
	2	5,876,931	3,12/99	Holden	<u> </u>		SEPI	n ana
			Foreig	n Patent Documents	5			
	•		T	·	-	TE	CH CENTER	a1600/2
		Document	Date	Country	Class	Subclass	Yes	No
	3	WO 99/40189	12 Aug.					
	(OTHER ART (Inc	luding Autho	r, Title, Date, Pe	ertinent	Pages, Etc	.)	•
	4	neuroendocri	ne cells and	s, "The granin pro tools for the dia 17:207-225 (1994)		_		nors,"
	5	Ottiger, H.P. et al., "1B1075: A Brain- and Pituitary-Specific mRNA that Encodes a Novel Chromogranin/Secretogranin-like Component of Intracellula: Vesicles," <u>J. Neurosci.</u> , 10(9):3135-3147 (1990) Dopazo, A. et al., "Primary Structure of Mouse Secretogranin III and Its Absence from Deficient Mice," <u>J. Mol. Neurosci.</u> , 4(4):225-233 (1993)						
	6							
	7	Kingsley, D. et al. "Genetic ablation of a mouse gene expressed specifical in brain," The EMBO J., 9(2):395-399 (1990)						
	8	Holthuis, J. et al., "Secretogranin III Is a Sulfated Protein Undergoing Proteolytic Processing in the Regulated Secretory Pathway," J. Biol. Chem., 271(30):17755-17760 (1996)						
						_		
	9	Hendy, G. et (1995)	al., "REVIEW	W: Chromogranin A,	" Clin.	Invest. Med	<u>l.</u> , 18(1):	47-65
	9	(1995)	t al., "BRCA	l is secreted and				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

OPPORTABLES ORIGINALLY FILED OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OPEG	11	Lee, N. et al., "Comparative expressed-sequence-tag analysis of differential gene expression profiles in PC-12 cells before and after nerve growth factor treatment," Proc. Natl. Acad. Sci. USA , 92:8303-8307 (1995)
SEP 0 9 7002	12	Dopazo, A. et al., GenBank Sequence Database, Accession AAA56636 (GI 413764), 7 Dec. 1994
TRADEMAS	13	Dopazo, A. et al., GenBank Sequence Database, Accession U02982 (GI 413763), 7 Dec. 1994
	14	Rogister, B. et al., GenBank Sequence Database, Accession CAA69961 (GI 1771306), 8 Jan. 1997
	15	Rogister, B. et al., GenBank Sequence Database, Accession Y08702 (GI 1771305), 8 Jan. 1997
	16	Weis, K. et al., "The Endoplasmic Reticulum Calcium-binding Protein of 55 kDa Is a Novel EF-hand Protein Retained in the Endoplasmic Reticulum by a Carboxyl-terminal His-Asp-Glu-Leu Motif," <u>J. Biol. Chem.</u> , 269(29):19142-19150 (1994)
		RECEIVED
		SEP 1 0 2002
		TECH CENTER 1600/2900
Examiner		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.

